Andrew Bergersen, MD
Urology · Robbinsdale, MNNPI 1063899250
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,505 of the $5,143 with a category attached, or 87.6%. It is spread thinly across 34 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,718 and has fallen 62.4% since, to $646 in 2025.
Across 109 payments — averaging $47.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Procept Biorobotics Corporation$908
- Boston Scientific$542
- Coloplast$391
- Axonics, Inc.$384
- Medtronic$333
- Teleflex LLC$309
- plus $2K from 28 others
What the payments were for
- Travel & lodging$62312%
- Food & beverage$4,50588%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Procept Biorobotics Corporation | 7 | $908 |
| Boston Scientific | 8 | $542 |
| Coloplast | 11 | $391 |
| Axonics, Inc. | 4 | $384 |
| Medtronic | 5 | $333 |
| Teleflex LLC | 3 | $309 |
| SRS Medical Systems, Inc. | 2 | $293 |
| Laborie Medical Technologies Corp. | 4 | $234 |
| Olympus America Inc. | 4 | $208 |
| Convatec Inc. | 7 | $152 |
| KARL Storz Endoscopy-america | 1 | $150 |
| Conmed Corporation | 1 | $138 |
| Agiliti Surgical, Inc. | 1 | $130 |
| Antares Pharma, Inc. | 8 | $119 |
| Angiodynamics, Inc. | 1 | $108 |
| AbbVie | 7 | $106 |
| Johnson & Johnson(2 entities) | 6 | $94 |
| Accord Healthcare, Inc. | 4 | $88 |
| Progenics Pharmaceuticals, Inc. | 5 | $84 |
| Dendreon Pharmaceuticals LLC | 2 | $46 |
| Merck | 3 | $44 |
| Myovant Sciences Inc. | 2 | $42 |
| Davol Inc. | 2 | $40 |
| Caris MPI, Inc. | 1 | $24 |
| Cook Medical LLC | 1 | $23 |
| 180 Medical, Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $19 |
| Blue Earth Diagnostics | 1 | $19 |
| Calyxo, Inc. | 1 | $16 |
| Tempus AI, Inc | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$594
- UroCuff$293
- Axonics$290
- HOPKINS$150
- UroLift$149
- Luja Coude$142
- iTIND System$141
- AIRSEAL$138
- UroLift System$136
- INTERSTIM$130
- Sonablate$130
- AMS$122
- REZUM$116
- GENERAL KIDNEY STONE DISEASE$109
- Nanoknife$108
- Porges Coloplast$107
How this compares
$5,143 in reported general payments places this provider in the 80th percentile of 247 urology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 32 | $443,348 |
| GemtesaVibegron | 81 | $70,928 |
| MyrbetriqMirabegron | 41 | $38,316 |
| Tamsulosin Hcl | 450 | $8,974 |
| Methenamine Hippurate | 52 | $6,287 |
| Trospium Chloride ErTrospium Chloride | 16 | $4,677 |
| Estradiol | 45 | $2,649 |
| Oxybutynin Chloride ErOxybutynin Chloride | 98 | $2,398 |
| Finasteride | 129 | $2,147 |
| Oxybutynin Chloride | 57 | $1,048 |
| Cephalexin | 92 | $1,029 |
| Tadalafil | 16 | $788 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 25 | $574 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 215 | $509 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 17 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $14 | $481,66473 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $14 | $70,92881 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 urology providers in Minnesota.
Other urology in Robbinsdale
- Neil SkempRobbinsdale$5K
- Joseph CernyRobbinsdale$4K
- David YangMankato$298K
- Steven BernsteinEdina$271K
- Ayman SoubraMinneapolis$204K
- Sean ElliottMinneapolis$163K
- Jonathan WarnerRochester$144K
- Steven SiegelWoodbury$140K
- Aaron MilbankWoodbury$97K
- Tobias KohlerRochester$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.